Patients with metabolic dysfunction-associated steatotic liver disease (MASLD) or metabolic dysfunction-associated steatohepatitis (MASH) and hepatic fibrosis who received resmetirom had lower rates of major adverse cardiovascular events (MACE) and all-cause mortality than matched patients receiving semaglutide, according to findings from a real-world analysis presented at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting in Nashville, Tennessee.1The poster, presented by Jalal Samhoun, MD, Florida Atlantic University, addresses a gap the investigators identified: there are no comparative cardiovascular outcome data between the 2 therapies, even though cardiovascular disease contributes heavily to morbidity and mortality in MASLD and MASH.1How Resmetirom and Semaglutide Compare for MASH With FibrosisResmetirom is an oral, liver-directed, thyroid hormone receptor-β agonist.
In March 2024, the US Food and Drug Administration (FDA) granted it accelerated approval for noncirrhotic MASH with moderate to advanced fibrosis.
It was the first drug approved for the disease.
In the phase 3 MAESTRO-NASH trial, MASH resolution without worsening of fibrosis occurred in 25.9% and 29.9% of patients receiving resmetirom 80 mg and 100 mg, respectively, versus 9.7% with placebo.
Low-density lipoprotein cholesterol fell by 13.6% and 16.3% at week 24.2
Patients with metabolic dysfunction-associated steatotic liver disease (MASLD) or metabolic dysfunction-associated steatohepatitis (MASH) and hepatic fibrosis who received resmetirom had lower rates of major adverse cardiovascular events (MACE) and all-cause mortality than matched patients receiving semaglutide, according to findings from a real-world analysis presented at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting in Nashville, Tennessee.1
The poster, presented by Jalal Samhoun, MD, Florida Atlantic University, addresses a gap the investigators identified: there are no comparative cardiovascular outcome data between the 2 therapies, even though cardiovascular disease contributes heavily to morbidity and mortality in MASLD and MASH.1
How Resmetirom and Semaglutide Compare for MASH With Fibrosis
Resmetirom is an oral, liver-directed, thyroid hormone receptor-β agonist. In March 2024, the US Food and Drug Administration (FDA) granted it accelerated approval for noncirrhotic MASH with moderate to advanced fibrosis. It was the first drug approved for the disease. In the phase 3 MAESTRO-NASH trial, MASH resolution without worsening of fibrosis occurred in 25.9% and 29.9% of patients receiving resmetirom 80 mg and 100 mg, respectively, versus 9.7% with placebo. Low-density lipoprotein cholesterol fell by 13.6% and 16.3% at week 24.2
